Renaissance Technologies LLC Takes $106,000 Position in Catabasis Pharmaceuticals, Inc. (CATB)

Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 66,100 shares of the biotechnology company’s stock, valued at approximately $106,000. Renaissance Technologies LLC owned about 0.35% of Catabasis Pharmaceuticals as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: This story was first published by BBNS and is owned by of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://baseballnewssource.com/markets/renaissance-technologies-llc-purchases-shares-of-66100-catabasis-pharmaceuticals-inc-catb/1604264.html.

A number of equities research analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. dropped their target price on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. HC Wainwright boosted their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research downgraded Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 19th. Finally, Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Catabasis Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $4.50.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) traded up 0.5536% during midday trading on Friday, reaching $1.6893. The company had a trading volume of 720,338 shares. The company’s market capitalization is $37.98 million. Catabasis Pharmaceuticals, Inc. has a 12-month low of $1.08 and a 12-month high of $7.89. The stock has a 50-day moving average price of $1.51 and a 200 day moving average price of $1.33.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current year.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.